Company profile: Incyte Pharmaceuticals, Inc.
Company overview. The tracked entity, Incyte Pharmaceuticals, Inc., is the original name of today's Incyte Corporation (Nasdaq: INCY). Founded in Palo Alto, California in 1991 and incorporated in Delaware, the company went public in 1993, was renamed Incyte Genomics in 2000 and Incyte Corporation in 2003, and is now headquartered in Wilmington, Delaware. It is a public, independent operating company: roughly 2,844 employees, FY2025 total revenue of ~$5.14 billion, net income of ~$1.29 billion, and a market capitalization of roughly $25 billion as of September 2026.
Products / operations. Incyte is a commercial biopharmaceutical company discovering and selling small-molecule and biologic therapeutics in hematology/oncology and inflammation/autoimmunity (including dermatology). Its marketed products include Jakafi (ruxolitinib), Opzelura, Iclusig, Pemazyre, Monjuvi/Minjuvi, Niktimvo, and Zynyz, plus royalty income from partner-marketed drugs (Novartis's Jakavi/Tabrecta and Lilly's Olumiant). At the time of its sole tracked suit (1998), however, the company was a genomics-data and gene-expression-services business operating in Palo Alto/Fremont, California — selling genomic database subscriptions and, after acquiring Synteni in January 1998, spotted DNA microarray (GEM) products and services.
Patent-litigation posture. Incyte is an operating company, not an NPE, and its tracked history shows a single appearance as defendant (1 case, 0 as plaintiff). That suit was a 1998 competitor-vs-competitor patent dispute with Affymetrix (maker of GeneChip arrays), not an assertion by a patent-holding entity. The case was filed in the District of Delaware and transferred to the Northern District of California — no plaintiff-friendly Texas venue activity is present.
Notable case. Affymetrix, Inc. v. Synteni, Inc. et al. (filed January 6, 1998) alleged that Synteni and Incyte infringed Affymetrix patents covering high-density DNA arrays after Incyte acquired Synteni and began marketing competing microarrays; press coverage notes Incyte countersued. The dispute centered on DNA microarray/gene-expression technology — the focus of Incyte's genomics-era business that it later divested in the early 2000s before pivoting to drug development. No other patent suits involving Incyte appear in the tracked database.
Sources: Incyte FY2025 Form 10-K and press release (Feb. 2026); stockanalysis.com; Science (1999); BioCentury (2001); casemine.com (D. Del. transfer opinion).